Journal for ImmunoTherapy of Cancer (Nov 2022)

Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia

  • Shuo Li,
  • Bin Zhang,
  • Jeffrey S Miller,
  • Veronika Kremer,
  • Bahram Valamehr,
  • Frank Cichocki,
  • Martin Felices,
  • Karl-Johan Malmberg,
  • Hans-Gustaf Ljunggren,
  • Björn Önfelt,
  • Laura Bendzick,
  • Evren Alici,
  • Alvaro Haroun-Izquierdo,
  • Marianna Vincenti,
  • Herman Netskar,
  • Hanna van Ooijen,
  • Minoru Kanaya,
  • Pouria Momayyezi,
  • Merete Thune Wiiger,
  • Hanna Julie Hoel,
  • Silje Zandstra Krokeide,
  • Geir Tjonnfjord,
  • Stéphanie Berggren,
  • Kristina Wikström,
  • Pontus Blomberg,
  • Petter Höglund,
  • Andreas Björklund,
  • Quirin Hammer,
  • Lise Kveberg,
  • Ebba Sohlberg

DOI
https://doi.org/10.1136/jitc-2022-005577
Journal volume & issue
Vol. 10, no. 11

Abstract

Read online

Background Natural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)+NKG2C+ adaptive NK cells to maximize missing-self reactivity.Methods We developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML.Results ADAPT-NK cells were >90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45dim blast subtypes.Conclusions These preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability.